ViCas® CRISPR Gene Editing and Retrotransposon Targeted Gene Integration
Our proprietary AaCas12bMax CRISPR gene editing system offers excellent mammalian cell on-target editing efficiency combined with minimal to none off-target editing, providing a relatively safer and more effective gene editing tool to site-specifically knock-out or insert genes-of-interest for a wide-range of ex vivo and in vivo applications.Click for BD contact details
In addition, we continue to develop the next-generation high efficiency targeted gene integration tools, such as Prime-In and engineered R2 retrotransposons to achieve durable expression of functional proteins for the cure of diseases with unmet medical needs.
ViLNP® Lipid Nanoparticle Delivery
Our independently developed ionizable cationic lipid molecule (L52715) possesses very high delivery capacity and an ultra-fast in vivo degradation rate, supporting high-dose and high-frequency gene drug delivery.
Our proprietary extrahepatic targeted delivery technology enables specific delivery to APCs, T cells, and HSCs, expanding the development of tumor vaccines and in vivo CAR-T cell therapy products.
The ViLNP® Lipid Nanoparticle Delivery Technology Platform is open for collaboration.Click for BD contact details
ViVec® AAV Production
We have established a commercial plant to manufacture both gene and cell therapies in accordance with the GMP standards. To ensure high quality AAV production, an engineered proprietary serum-free high-density suspension ViHiYi® 293 cell line, along with a multi-element biological module-containing main backbone and a proprietary plasmid DNA bank that includes auxiliary and packaging plasmids for AAV manufacturing have been developed and successfully used in our clinical programs.